Please assess the completion status of the following clinical trial:

Trial Title: Effect of HCO1100 on Cardiovascular Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Dialysis dependent chronic renal failure (CKD 5) in a stable condition~* Serum albumin at randomisation equal to or above the median of the normal range (pre- dialysis value)~Exclusion Criteria:~* Diabetes mellitus as the disease underlined end stage renal failure~* Haemodynamic instability that precludes unsupported dialysis~* planned surgical interventions \<= 4 months at time of inclusion~* known allergy against dialysis membranes~* Significant cardiac disease (atrial fibrillation, myocardial infarction within 6 months; unstable angina pectoris; LV-EF \< 30%, clinically significant pericardial disease; cardiac amyloidosis)~* pulmonary disease with chronic hypoxia~* Advanced disease or significant co-morbidity with poor short term prognosis, necessitating palliation and not subject to active or disease specific treatment~* Clinically significant liver dysfunction (bilirubin \> 1.8mg/dl (30µmol/L))~* Prior fistula surgery on both arms or other operations or paralysis on both arms~* Known HIV, HCV infection~* Alcoholism~* Active uncontrolled infection~* Pregnancy or lactation~* Inability to give informed consent to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dialysis treatment with HCO1100 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).